EVAX Stock Overview
A clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Evaxion Biotech A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.88 |
| 52 Week High | US$13.82 |
| 52 Week Low | US$2.26 |
| Beta | -0.27 |
| 11 Month Change | 7.87% |
| 3 Month Change | -33.18% |
| 1 Year Change | -76.59% |
| 33 Year Change | -95.17% |
| 5 Year Change | n/a |
| Change since IPO | -97.09% |
Recent News & Updates
Recent updates
Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration
Mar 31Evaxion Biotech names Per Norlén as CEO
Oct 05Evaxion stock rises 11% as enrollment begins in trial of immunotherapy EVX-01 for skin cancer
Sep 21Evaxion Biotech ADS GAAP EPS of -$0.20 beats by $0.10
Aug 10Evaxion Biotech announces new CEO as Lars Wegner resigns
Aug 02Is Evaxion Biotech (NASDAQ:EVAX) In A Good Position To Invest In Growth?
Oct 27
We're Hopeful That Evaxion Biotech (NASDAQ:EVAX) Will Use Its Cash Wisely
Jun 29Evaxion Biotech posts preclinical proof of concept data for AI-powered vaccine platform
Jun 03Shareholder Returns
| EVAX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.0% | 0.3% | -0.7% |
| 1Y | -76.6% | 12.0% | 20.2% |
Return vs Industry: EVAX underperformed the US Biotechs industry which returned 14.6% over the past year.
Return vs Market: EVAX underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| EVAX volatility | |
|---|---|
| EVAX Average Weekly Movement | 9.9% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: EVAX's share price has been volatile over the past 3 months.
Volatility Over Time: EVAX's weekly volatility has decreased from 24% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 49 | Christian Kanstrup | www.evaxion-biotech.com |
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy that is in pre-clinical stage for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases.
Evaxion Biotech A/S Fundamentals Summary
| EVAX fundamental statistics | |
|---|---|
| Market cap | US$15.64m |
| Earnings (TTM) | -US$14.69m |
| Revenue (TTM) | US$124.00k |
125.7x
P/S Ratio-1.1x
P/E RatioIs EVAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EVAX income statement (TTM) | |
|---|---|
| Revenue | US$124.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$124.00k |
| Other Expenses | US$14.81m |
| Earnings | -US$14.69m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.71 |
| Gross Margin | 100.00% |
| Net Profit Margin | -11,846.77% |
| Debt/Equity Ratio | 0% |
How did EVAX perform over the long term?
See historical performance and comparison